Fact CheckerSign in

NCT04033120Completed

Making an Early Diagnosis of Talaromycosis Using a Novel Antigen Test

Making an Early Diagnosis of Talaromycosis - a Strategy to Reduce Morbidity and Mortality in Advanced HIV Disease in Southeast Asia

Source: ClinicalTrials.gov · Last updated 7 Feb 2025

Brief summary (registry, in English)

This is a research study to determine whether a new antigen detection test called Mp1p EIA can make an early diagnosis of talaromycosis from the blood and urine of patients. Talaromycosis is a life-threatening infection caused by a fungus endemic in Southeast Asia commonly found in patients with advanced HIV disease called Talaromyces marneffei.

Status (registry)
Completed
Study type
Observational
Enrollment
1411 (actual)
First submitted
23 Jul 2019
Start date
22 Feb 2021
Primary completion date
31 Dec 2024
Lead sponsor
Duke University
Diseases
HIV
NCT number
NCT04033120

What you commit to

  • Study type: Observational
  • Participants enrolled: 1411
  • From 22 Feb 2021 to the primary completion date, 31 Dec 2024
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • History of recent talaromycosis or histoplasmosis infection currently on antifungal therapy

Other

  • Unlikely to attend regular clinic visits

Who the study is looking for

  • HIV-1 infection (at least 2 of 3 HIV antibody tests are positive), AND
  • HIV-infected age ≥18 years, AND
  • CD4 count ≤100 cells/mm3 within the past 3 months, AND
  • Antiretroviral therapy (ART) naïve OR recent ART ≤3 months OR suspected or confirmed treatment failure on ART ≥12 months (defined as poor treatment adherence, treatment interruption, or having a confirmed HIV RNA ≥1,000 copies)
  • Cohort 1: suspected to have an active infection
  • Cohort 2: not suspected to have or being evaluated for an active infection

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
National Hospital for Tropical Diseases
Coordinator of this site? Confirm its status
Hà NộiVietnamUnknown status
Hospital for Tropical Diseases
Coordinator of this site? Confirm its status
Ho Chi Minh CityVietnamUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.